Abstract
Chronic insomnia occurs in ~10% of the general population and has numerous negative health effects. The recommended first line treatment of cognitive behavior therapy for insomnia is not widely available for patients in Europe, so pharmacotherapies such as benzodiazepine receptor agonist agents (benzodiazepines and Z-drugs) are commonly used. However, their use is only recommended for ≤4 weeks due to unproven long-term efficacy in treatment of chronic insomnia, and the risk of tolerance, and the potential for dependence and misuse. In Europe, recommendations limiting the use of benzodiazepines (lowest dose and shortest duration) in chronic insomnia are not always followed, likely due to the lack of approved effective alternative therapies. Here we present a recent pilot survey of the pharmacological treatment landscape in chronic insomnia in five European countries (France, Germany, Italy, Spain, and the United Kingdom) and physicians’ attitude toward treatment. The results suggest that benzodiazepines and Z-drugs are the most widely used treatments in chronic insomnia and are being used for longer than their recommended duration. Country variations in prescription rates were observed. Due to the known association between long-term benzodiazepine use and potential for developing dependence, further analysis of the literature was performed on the use and misuse of benzodiazepines. The results show that long-term use of benzodiazepines is associated with multiple consequences of treatment, including dependence, but also that previous use of benzodiazepines may increase the risk of opioid use disorder.
1. Introduction
Sleep is integral to the maintenance of key processes in the body, including energy conservation, metabolic waste clearance, memory consolidation, and the modulation of inflammation and immunity (). Sleep is also recognized as one of eight essential components of cardiovascular health by the American Heart Association (). Both sleep quantity and sleep quality are fundamental components of sleep ().
Insufficient sleep is associated with numerous negative health effects and is a prevalent healthcare challenge worldwide (), with the full clinical syndrome of chronic insomnia occurring in ~10% of the general population (). The coronavirus disease 2019 (COVID-19) pandemic is reported to have driven an increase in the global prevalence of clinically significant insomnia to 16.7% (). In Europe, prevalence estimates for chronic insomnia vary between countries (Table 1). Many patients with symptoms of insomnia lasting for years do not consult their physician and obtain a formal diagnosis (, ), suggesting that chronic insomnia is often under-reported.
Table 1
| Country | Prevalence |
|---|---|
| Switzerland | 11% of adults aged ≥18 years met DSM-5 criteria for chronic insomnia () |
| Germany | Prevalence of chronic insomnia was reported as 4% () |
| France | Chronic insomnia was reported in 15.8% of the population () |
| United Kingdom | Incidence of insomnia lasting ≥12 months was reported as 15% () |
| Italy | Chronic insomnia was reported in 13.2% of adults () |
Prevalence of chronic insomnia reported in various European countries.
DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
Psychiatric disorders are the most common comorbidities associated with insomnia () and insomnia can be a symptom or harbinger of other psychiatric disorders (). It is estimated that 40% of all insomnia patients have a coexisting psychiatric condition (, ). Depression is the most common of these conditions and the presence of insomnia is considered a transdiagnostic symptom for depressive and anxiety disorders (). Given the detrimental effects of insomnia on mental health, severity of daytime symptoms and recovery/remission of mental disorders, in patients with comorbid psychiatric illness and insomnia clinicians therefore need to address both conditions to achieve optimal treatment outcomes ().
Chronic insomnia disorder is defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3) as having sleep disturbance and associated daytime symptoms occurring at least three times per week, and present for at least 3 months (). In the ICSD-3, short-term insomnia disorder is characterized by sleep/wake difficulties that fail to meet the minimal frequency and duration criteria of chronic insomnia disorder (). The current version of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) adopts a similar approach to the ICSD-3 in specifying that those affected by chronic insomnia disorder have sleep difficulty occurring at least 3 nights per week, and this is present for at least 3 months, whereas acute−/short-term insomnia is defined as meeting the same diagnostic criteria, but with symptoms lasting less than 3 months ().
Treatment guidelines for chronic insomnia include both non-pharmacological and pharmacological options (, ). At first line, cognitive behavioral therapy for insomnia (CBTi) is recommended in adults of any age by the European Sleep Research Society (ESRS) and in national guidelines for insomnia and sleep disorders for European countries (, ). However, in practice, use of CBTi appears to be limited in Europe. For example, in a survey by the European Insomnia Network (EIN) among 12 countries that are founding members of its CBTi Academy, only approximately 600 and 300 patients were estimated to have received CBTi annually in Norway and Italy, respectively (). In France, it was estimated that only 15–30 centers (mostly academic hospitals with a sleep clinic) offered CBTi (). The EIN highlighted that differences in healthcare systems across Europe do not represent a barrier to the availability of pill-based solutions, however the structure of health services and associated reimbursement mechanisms may play a part in “rationing” access to CBTi (). They also noted that, because CBTi is traditionally delivered face-to-face, the shortage of training in this therapy represents an intrinsic limitation to the scalability of CBTi to meet population need and demand (). In addition, although general practitioners (GPs) have a pivotal role in treating patients with insomnia, they rarely prescribe or are able to offer CBTi ().
If CBTi is not deemed sufficiently effective, is not available, or is inaccessible to patients, pharmacological interventions–namely benzodiazepine (BZD) receptor agonists such as BZDs or Z-drugs (ZDs), and some sedating antidepressants–can then be offered (). In insomnia, BZDs and ZDs are indicated for short-term use only and there are several BZD hypnotics available for this indication. Regulatory bodies in many countries, including France, Germany, Italy, Spain, and the United Kingdom, have issued guidance to regulate and limit the use of BZDs and other similar drugs to a maximum duration of 2–4 weeks due to the concerns linked with dependence, tolerance, and substance abuse (, , , , ). Positive long-term effects of BZDs are not proven ().
Although multiple publications address the use of BZDs in chronic insomnia, quantitative data at the European level are lacking, and it is unclear whether the advice that “Long-term treatment of insomnia with BZ or BZRA is not generally recommended because of a lack of evidence and possible side-effects/risks” given by the ESRS 2017 guideline is being followed. This manuscript aims to explore the hypothesis that prolonged use of BZDs in the treatment of chronic insomnia may still be relatively common in Europe. We assessed the results of a series of pilot market research studies of the treatment landscape of chronic insomnia focused on five European countries (France, Germany, Italy, Spain, and the United Kingdom). This analysis included an examination of the duration of treatment with BZDs and ZDs in insomnia. Based on the resulting observations, we discuss some of the known and emerging awareness of risks associated with prolonged use of BZDs in the treatment of chronic insomnia. Where relevant, we also compare and contrast the information on BZDs with the data related to the use of ZDs. Within the literature, the risk profile of ZDs has not been characterized to the same depth as that for BZDs, so we have focused most of our discussions on the BZD class.
2. Methods
Pilot market research studies were commissioned by Idorsia to better understand and quantify the use of BZDs in insomnia in Europe. The methodology for these studies is described in brief below.
2.1. Primary research among healthcare professionals working in insomnia
This dataset comes from a primary market research (PMR) study conducted by Ipsos (Ipsos).1 Ethics committee approval was not required as Market Research as defined in Section 1 of the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct does not require Clinical Research Ethics Committee or Independent Review Board approval (). Data gathering involved a 30-min online questionnaire which was open to general practitioners (GPs), sleep specialists, neurologists, and/or psychiatrists involved in clinical management of people with insomnia. The questionnaire is included as supplementary material online.
The questionnaire was broadly divided into the following topic areas:
Profiling questions, including work setting and numbers of years in practice
Insomnia caseload, including number of patients seen and number of chronic versus acute insomnia patients
Perception of insomnia, including how physicians perceive insomnia as a condition, how challenging they find it to manage and how much insomnia impacts on the lives of their patients
Attitudes toward insomnia treatment and management, including perception toward different insomnia treatments covering different classes of prescriptions, and toward monitoring and follow-up of patients
Treatment usage, including how different insomnia treatments are prescribed
Attitudes toward a blinded insomnia treatment profile
Relationship with patients
To be eligible for participation in this survey, healthcare professionals (HCPs) needed to have been in their current role for at least 3 years, to spend at least 70% of their time seeing patients, and to treat at least 15 adult patients with insomnia per month. Participating physicians were recruited from a professional HCP panel for market research, for which they had previously registered and provided consent to be contacted for market research studies. Participants who met the eligibility criteria and completed the questionnaire received compensation for their time.
2.2. Secondary research on longitudinal prescriptions relating to insomnia
To evaluate whether the HCPs’ estimate of BZD and ZD use was aligned with prescribing data, longitudinal patient prescription activity was analyzed for European countries of interest with relevant datasets available (France, Germany, and the United Kingdom). In each of these countries, data for the top 5–6 molecules was acquired.
The analyzes of longitudinal prescriptions relating to insomnia were originally performed in March 2021. For France and Germany, IQVIA Longitudinal Prescription Data (LRx) datasets (IQVIA)2 of retail pharmacy prescriptions were screened for patient prescriptions relating to sleeping disorders. For the United Kingdom, the IQVIA Longitudinal Patient Dataset (LPD) containing information from electronic medical records of GP-treated patients was screened for prescriptions relating to sleeping disorders. The LRx and LPD datasets allowed a look-back period of at least 12 months. All analyzed data were anonymized (no patient identifiers were present) and GDPR compliant.
2.3. Secondary research on volume per class for medicines prescribed in insomnia
In this study, total volume of sales with an indication for insomnia [specifically, prescription of non-barbiturate hypnotics/sedatives in the European Pharmaceutical Marketing Research Association’s N5B1 anatomical classification for the treatment of insomnia ()] over the previous 12 months was calculated for the five European countries of interest using data from the IQVIA MIDAS® platform (IQVIA, see text footnote 2). The N5B1 classification includes BZDs which are used mainly for insomnia, ZDs and melatonin receptor agonists. BZDs used for other indications and sedating antidepressants are categorized within the N5C (Antidepressants and Anxiolytics) classification, so were not included in our analyzes. The MIDAS® platform provides an estimate of national-level sales to retail and/or hospital pharmacists from data collected at a local level. To compare data for medicines having different dosing regimens, standard units were defined to represent the smallest daily unit of consumption for each drug of interest, e.g., one tablet. Results for each drug class are presented as the proportion of standard units for that drug per million standard units of N5B1 medicines sold.
3. Results
3.1. Primary research among healthcare professionals working in insomnia
Between April 2021 and May 2021, this study enrolled 602 HCPs from five representative European countries (France, Germany, Italy, Spain, and the United Kingdom; Table 2). GPs made up the highest proportion of participants (n = 361; 60.0%), followed by psychiatrists (n = 161; 26.7%), neurologists (n = 41; 6.8%), and sleep specialists (n = 39; 6.5%). These proportions were consistent across the five countries surveyed.
Table 2
| Total | General practitioners | Sleep specialists | Neurologists | Psychiatrists | |
|---|---|---|---|---|---|
| United Kingdom | 120 | 72 | 6 | 9 | 33 |
| Spain | 120 | 72 | 7 | 9 | 32 |
| Italy | 120 | 72 | 8 | 10 | 30 |
| Germany | 121 | 73 | 7 | 7 | 34 |
| France | 121 | 72 | 11 | 6 | 32 |
| Total | 602 | 361 | 39 | 41 | 161 |
Healthcare professionals participating in online survey on management of insomnia.
When asked to estimate their typical duration of use of BZDs and ZDs in patients with insomnia, across the five countries, the average was 15.3 [standard deviation (SD): 23.0] weeks for BZDs [ranging from 7.1 (SD: 12.0) weeks in the United Kingdom to 23.0 (SD:20.3) weeks in Spain] and 17.8 (SD: 23.9) weeks for ZDs [ranging from 8.1 (SD: 16.3) weeks in the United Kingdom to 23.8 (SD:24.3) weeks in Italy] (Figure 1).
Figure 1
Across the countries surveyed, HCPs acknowledged that their use of BZDs and ZDs typically extends beyond the limit of ≤4 weeks recommended for these agents () and the drug labels. As these survey results are based on the HCPs’ recollection, the average duration of use may be subject to bias. For example, results may be impacted by recall bias (e.g., not remembering previous events or experiences accurately or omitting details) or social desirability bias (e.g., underestimating the actual duration of treatment, if respondents perceived that a shorter duration of use was preferred by their peers) ().
3.2. Secondary research on longitudinal prescriptions relating to insomnia
The longitudinal prescription data showed that the average duration of treatment with BZDs prescribed for insomnia ranged from 62 days (8.9 weeks) for lorazepam in Germany to 230 days (32.9 weeks) for alprazolam and oxazepam in France (Figure 2). There were insufficient data for BZD prescriptions for insomnia in the United Kingdom LPD dataset to calculate the average duration of BZD use in this country.
Figure 2
Across the three countries examined, the average duration of treatment with ZDs ranged from 70 days (10 weeks) to 141 days (20.1 weeks) (Figure 2). In France and Germany, patients with insomnia were mainly treated with either zolpidem or zopiclone; whereas, in the United Kingdom, only zopiclone was prescribed.
Despite prescribing data not being available for all five of the countries of interest, the results that were available support the HCP questionnaire survey findings, demonstrating that the duration of BZD and ZDs prescriptions in Europe extend beyond the recommended limit of ≤4 weeks for these agents.
3.3. Secondary research on volume per class for medicines prescribed in insomnia
Analyzes performed in July 2022 showed that, across the five countries examined, BZDs and ZDs accounted for 92% of the total volume of prescribed medicines indicated for insomnia (Figure 3). The sales by volume for BZDs were highest in Italy and Spain, where they made up 66.3 and 64.8% of the total, respectively. In contrast, in Germany and the United Kingdom, the sales by volume for BZDs were much lower, at 14 and 10% of the total, respectively. The sales by volume for ZDs ranged from 32% of the total in Italy to 83% of the total in Germany. Across the five countries, sales by volume of long-acting formulations of melatonin were lower than that for BZDs and ZDs, with the exception of the United Kingdom, where melatonin accounted for 31% of sales versus 14 and 55% for BZDs and ZDs, respectively. Long-acting melatonin is licensed for use in adults aged >55 years old for up to 13 weeks as a treatment for primary insomnia (), however the current European guideline does not recommend melatonin for the treatment of insomnia because of low efficacy ().
Figure 3
These data show that BZDs contribute a high proportion of total sales by volume for N5B1 medicines prescribed in insomnia (on average, 40% across the five countries examined). It is also important to consider that there may be additional prescribing of BZDs that do not have a licensed indication for use in insomnia (e.g., alprazolam, lorazepam, and oxazepam). Thus, even in countries with apparently lower BZD sales by volume (Germany and the United Kingdom), there may be additional usage of BZDs that is not captured in the data shown.
4. Discussion
The results from this series of pilot market research studies demonstrate that BZDs are widely used across European countries in the management of insomnia and the duration of treatment is longer than recommended. To determine whether published data align with these findings, we examined relevant areas of the literature (it should be noted that most published reports on BZD duration of use are not specific for use in insomnia, but are believed to include a proportion of patients using BZDs for this indication).
Both acute and chronic insomnia symptoms have a high prevalence in the general population, partly due to insomnia disorder often being comorbid with psychological or somatic disorders (). The 3P model for insomnia etiology suggests that predisposing, precipitating, and perpetuating factors influence the onset and maintenance of chronic insomnia (). Predisposing factors exert influence throughout the entire course of the disorder making some individuals more vulnerable than others. Precipitating factors (such as stress) may fuel early insomnia, however their impact may diminish over time, whereas perpetuating factors, such as learned negative associations, may keep the individual over the insomnia threshold, resulting in chronic insomnia. In cases where insomnia symptoms are secondary to another condition, insomnia symptoms may persist after successful treatment of the main disorder due to perpetuating factors, so it is important for the physician to monitor how the patient is sleeping () and to continue to seek approaches to identify predisposing and perpetuating factors, even after the natural course of the precipitating factor(s) has subsided ().
In Europe, patients suffering from chronic insomnia typically visit their GPs after trying solutions such as over-the-counter sleeping aids, lifestyle changes (e.g., reducing caffeine intake, sleep hygiene), and, in some cases, meditation, yoga, etc. Due to the wide impact of chronic insomnia on multiple aspects of health and wellbeing and the heterogeneous population that suffers from this disorder, the management of chronic insomnia would ideally involve a multidisciplinary collaboration among HCPs such as GPs, psychiatrists, neurologists, and psychologists. However, in clinical practice, GPs often attempt to solve chronic insomnia with limited resources, e.g., lack of time for patient consultations, limited up-to-date knowledge about the condition, limited awareness and/or availability of CBTi, and lack of approved pharmacotherapy for chronic insomnia. As a consequence, if improvements in sleep hygiene (and CBTi, if tried) fail, GPs (and also specialists) may resort to using medications such as BZDs and ZDs for longer than recommended to treat chronic insomnia. Psychological and physical dependence on BZDs, which can develop within a few weeks of regular or repeated use (41) may also contribute to a longer duration of use.
Current pharmacological treatments may create a paradoxical situation: on one hand, such drugs should not be used long term, and on the other hand, they are being used to manage a chronic disease, which, by its own definition, lasts at least 3 months (, ). A second challenge is that although substance abuse/dependence are recognized as comorbidities in chronic insomnia (Table 3) (), BZDs that are used in treating insomnia carry the risk of tolerance and dependency (42). Furthermore, although the use of BZDs and ZDs is supported by moderate-quality evidence for the short-term treatment (≤4 weeks) of insomnia, with the exception of eszopiclone (43), the long-term efficacy of these drugs is not proven ().
Table 3
| Psychiatric | Medical | Neurological | Substance use/dependence |
|---|---|---|---|
|
|
|
|
Major comorbidities of insomnia.
Adapted from Riemann et al. (). HIV, human immunodeficiency virus.
4.1. Scale of the problem: prevalence of long-term BZD use
In our study, the HCP-estimated duration of use for BZDs was longest in Italy and Spain at 22 and 23 weeks, respectively, and shortest in Germany and the United Kingdom (at 10.9 and 7.1 weeks, respectively). Our pilot study methodology was not structured to determine factors which might explain differences in the pattern of BZD use between the countries surveyed. However, a recent global analysis of BZD and ZD sales data found that increased consumption of these drugs in countries was statistically associated (p < 0.05) with several factors including increased prevalence of anxiety, self-harm and neurological disorders (44). Other factors, such as differences in prescribers’ attitudes to the risks and benefits of long-term use of BZDs between countries may also be involved.
Globally, the prevalence of long-term BZD use is estimated at approximately 2.0–7.5% in the general population, with estimates for long-term use among BZD users ranging from 25 to 76% (45, 46). Focusing on European countries, the results appear to echo the global pattern. High use of BZDs can be seen across Europe, with variations between individual countries. France shows a particularly high use of BZDs compared with other European countries (47), as does Italy, where, according to a 2018 report of the Italian National Observatory on the Use of Medicines (Osservatorio Nazionale sull’Impiego dei Medicinali), BZDs are among the most purchased medications paid for in full by patients alongside ZDs (48). Further European data also establish that the duration of BZD use is often higher than guideline recommendations.
High proportions of people taking BZDs do so on a long-term basis, with 95.8% of all BZD prescriptions (in any indication, including insomnia) identified as being used off-label for longer than 3 months in Spain (49). Use of BZDs beyond 12 months is also evident elsewhere in Europe, with ~20% of all BZD prescriptions for any indication in Germany (50) and an estimated 35% of prescriptions for any indication in the United Kingdom (51) being of this duration. A median duration of BZD use (for any indication) of 7 months was recorded in one study in France (52), while in Italy, 64.2% of patients with insomnia had been taking hypnotics/sedatives for >3 years (53). Data from the Berlin Aging Study show that the mean period of BZD use for any indication was 7.6 years; 33.8% of patients in this study were treated with BZDs for 1–5 years, while 40.3% were treated with BZDs for >5 years (54, 55). In addition, COVID-19 lockdown confinements resulted in an increase in the use of hypnotics, including BZDs over the period between March 2020 and April 2021, with an additional 1.4 million deliveries of hypnotics compared to expected being recorded in France (56).
BZD misuse has also been observed among HCPs, who are at a high risk of sleep disorders linked to work-related stress. HCPs who are dependent on BZDs experience difficulties at work due to cognitive impairment, but they are usually ashamed to seek medical help and worried about the potential legal implications of their dependence (57, 58).
These examples from the literature further support the market research evidence that BZDs are used for longer than their indications including in chronic insomnia.
4.2. Challenges associated with long-term use of BZDs for the treatment of chronic insomnia
4.2.1. Development of dependence and tolerance can arise over time
While the risk–benefit ratio for BZDs remains positive in most patients over the indicated use of 2–4 weeks, this ratio is not stablished beyond that duration because of the difficulty of predicting the risk of dependence (42). There is an increased risk of dependence with long-term use; an estimated 20–50% of patients are believed to experience some sort of withdrawal when trying to discontinue BZDs (59), and 3–4% of them display clear signs of dependence (42, 60, 61). One study in France found that nearly half (49.8%) of adults aged 18–64 years old who were chronic users of BZDs (≥3 months and taking a BZD for any indication, including insomnia) were suffering from physical and psychological dependence (62).
Tolerance develops within a short time frame of 3–14 days of continuous BZD use, with effects of BZDs often wearing off after a few weeks and the potential of rebound insomnia with drug cessation (45, 63, 64). This high potential of tolerance, combined with the very low toxicity of BZDs, can induce consumption at extreme doses in an effort to maintain the hypnotic effect, whereas the effects of high-dose BZD withdrawal syndrome are very poorly tolerated and risky for the patient’s health (45, 65), so it can be difficult to wean patients from using these agents.
4.2.2. Pharmacology of BZDs and ZDs needs to be considered
BZDs and ZDs work by potentiating gamma-aminobutyric acid (GABA) activity (66), the principal inhibitory neurotransmitter in the human brain (67). While BZDs bind to the alpha-1, −2, −3, and − 5 GABA receptor subunits, ZDs selectively bind to the alpha-1 receptor subunit (66). Although the primary sites of action of BZDs are the GABA receptor subunits, they also indirectly enhance dopamine release in the nucleus accumbens (68). This increase in dopamine concentration is responsible for the addictive properties of BZDs and ZDs (69, 70).
In general, BZDs can offer anxiolytic (anxiety-reducing) or hypnotic (sleep-inducing) effects, with overlap between the two properties (71). BZDs can be categorized as short-acting [half-life (T1/2) <24 h] and long-acting treatment (T1/2 > 24 h) (72). BZDs available for use in insomnia include triazolam (T1/2: 1.5–5.5 h) (73), temazepam (T1/2: 8–15 h) (74), lormetazepam (T1/2: 11 h) (75), loprazolam (T1/2: 12.8 h) (76), nitrazepam (T1/2: 24–40 h) (77), flunitrazepam (T1/2: 18–26 h) (78), flurazepam (T1/2: 2.3–3.5 h; T1/2 of N1-des-alkyl-flurazepam: 19–133 h) (79), clonazepam (T1/2: 20–60 h) (80), and nordazepam (T1/2: 36–200 h) (81). Compared with BZDs, ZDs show a shorter duration of action and half-life (zopiclone, T1/2: 4–5 h; zolpidem, T1/2: 2.5 h; zaleplon, T1/2: ~1 h). Although their fast clearance helps minimize undesirable residual effects, too short a half-life can be a problem if patients require both sleep initiation and sleep maintenance therapy (82).
Short-acting hypnotics are preferable in patients with sleep onset insomnia, when sedation the following day is undesirable, or when prescribing for elderly patients. Long-acting hypnotics are indicated in patients with poor sleep maintenance (e.g., early morning waking) that causes daytime effects, when an anxiolytic effect is needed during the day, or when sedation the following day is acceptable (83). The risk-benefits of long- versus short-acting BZDs need to be considered on an individualized basis. For example, for short-acting BZDs relative to long-acting BZDs, withdrawal phenomena are more common (83, 84), and among people aged 65 years and older, there is a higher risk of developing dementia {adjusted odds ratios of 1.98 [95% confidence interval (CI): 1.89–2.07] and 1.47 [95% CI: 1.37–1.58] versus non-users of BZDs respectively} (85). In comparison, a meta-analysis found that long-acting BZDs are associated with a significantly higher risk for hip fractures than short-acting BZDs [relative risk: 1.31 (95% CI: 1.18–1.45) versus 1.15 (95% CI: 1.08–1.22), p < 0.0001, relative to non-BZD users, respectively] (86). A study in residential aged care facilities in Australia suggested that residents who used long-acting BZDs on a regular basis had higher night-time sleep quality versus those using short-acting BZDs taken on an as-needed basis (87).
Although ZDs have a shorter duration of action and more rapid clearance than BZDs, they can impair nocturnal and next-day psychomotor performance, including cognition, behavior, psychomotor performance, and driving ability (82, 88). Higher dose ZD use in people with dementia is associated with increased fracture and stroke risks, similar or greater to that for higher dose BZDs (89). In the United States, the FDA has required that all ZDs carry a Boxed Warning highlighting the risk of complex sleep behaviors (e.g., sleep-walking, falls and sleep-driving) which can result in serious injuries, including death (90).
4.2.3. Cognitive and central nervous system effects can impact patients’ lives
The negative effect of long-term use of BZDs on cognitive function has long been known, with meta-analysis data having reported moderate-to-large effects for all cognitive domains in long-term BZD users, including increased risk of motor vehicle collisions compared with non-BZD users (91, 92). An increased risk of development of dementia among BZD users has also been found in meta-analyzes (93, 94). This increase was observed for users of both long- and short-acting BZDs relative to non-users of BZDs (93). Studies in mice suggest that long-term but not short-term use of BZD impairs motoric function and upregulates neurotoxic amyloid β42 in part through suppression of neuroprotective translocator protein in the cerebellum, suggesting a potential mechanism for movement deficit and increased risk of falls seen in chronic BZD users (95).
Long-term use of BZDs is also correlated with further insomnia, anxiety, drug dependence, and depression (96). This may be a factor involved in the pattern of long-term use of BZDs without a label for insomnia that we observed, i.e., lorazepam, alprazolam and oxazepam (Figure 2). It is known that insomnia affects around half of individuals with anxiety (97), so by using these drugs, physicians may be attempting to address both insomnia and anxiety, despite their not being licensed for insomnia, and the products being licensed for short-term relief only in the treatment of anxiety due to concerns about tolerance and dependency (98). Physicians may keep using these BZDs for longer than recommended due to the lack of approved pharmacotherapy for chronic insomnia and/or the difficulties associated with BZD withdrawal syndrome mentioned previously.
High-dose BZD-dependent patients have been reported to have reduced quality of life directly associated with BZD intake compared with non-BZD users, both from a physical and emotional position, reduced social functioning, and high levels of psychological distress (99, 100).
Further evidence also warns against the long-term use of BZDs due to associations with long-term unfavorable effects, such as oversedation, depression, and impairment of the immune system (101). It has also been reported that, in contrast to short-term use at low therapeutic doses (which normalizes sleep microstructure), long-term use of high doses of a BZD for chronic insomnia induces a severe disruption of sleep microstructure (102).
4.2.4. Recommendations and contraindications in the product label may not be followed
Failure to adhere to recommendations and contraindications in the product label can occur in patients at risk of drug–drug interactions, patients with certain pre-existing medical conditions, or patients who are at a high risk for treatment-related adverse events (74, 75). For instance, high-dose use of BZDs and ZDs were found to be associated with attention deficit hyperactivity disorder (ADHD) (103), and use of high dose levels of long-acting BZDs, short-acting BZDs and Z-drugs were all found to significantly increase the risk of fall-related injuries requiring hospitalization in people aged 65 years and older (104). Due to the increased risk of falls, care is recommended when using BZDs in elderly subjects (). As ADHD is often associated with sleep disturbance, caution should also be taken when prescribing BZDs or ZDs in people with ADHD (105). Furthermore, BZDs may lower the threshold for suicidal behavior in patients with depression (71).
Caution is also needed for patients who are using other medications that may produce additive effects when co-administered with BZDs. This includes drugs/substances that produce depression of the central nervous system (CNS), such as alcohol, antipsychotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, and anticonvulsants (74, 75). As CNS suppressants, BZDs and ZDs can also act as respiratory depressants by suppressing one or more steps in respiration and patency (106). Indeed, long-term BZD use may cause complete obstructive sleep apnea in heavy snorers or short repetitive central sleep apnea in patients with recent myocardial infarction (107). In older patients (aged ≥66 years) with chronic obstructive pulmonary disorder, initiation of treatment with a BZD increases risk for outpatient respiratory exacerbations (108). Additionally, care should be taken for patients taking muscle relaxants, as the overall muscle-relaxing effect of BZDs may accumulate and increase the risk of falling in elderly patients and those on higher doses compared with those not on these medications (74, 75).
Before prescribing BZDs and ZDs in any patient with chronic insomnia, the risk of substance abuse should be assessed, as these drugs should be avoided in individuals with a history of drug or alcohol abuse (, 77).
4.2.5. Patients may misuse BZDs without understanding the risks
Ineffective communication of the health risks associated with long-term use and gaps in communication between patients and HCPs can contribute to the problem of misuse (109). Patients may be unwilling to listen to their HCP’s advice on the health risks of their medication and instead perceive BZDs as having a subjective positive risk–benefit ratio. If discontinuation is discussed by their HCP, they may seek to switch to another HCP who is more willing to prescribe BZDs (110).
Patients taking BZDs may have concerns that alternative therapies are less effective for treating chronic insomnia, and this commonly combines with apprehension of drug cessation without professional support and a fear of recurring symptoms upon discontinuation (109, 110).
Moving forward, it is fundamental that patients with chronic insomnia are investigated for the cause of their symptoms (predisposing, precipitating, and perpetuating factors), something that is often neglected because of a lack of resources for the management of long-term medication use, especially in older adults (109). Patients should also be evaluated for risk factors that may affect their BZD use, including likelihood of abuse and dependence, before prescription of any drug (111).
4.3. Recent links between BZD use and risk of opioid use
The link between use of BZDs and increased risk for future opioid abuse is an emerging area that warrants further research, especially as patients with insomnia are at risk of substance use/dependence (including opioids) as a comorbidity (). While overall opioid consumption per person and opioid-related mortality rates in Europe remain lower than in the United States (which has faced an opioid crisis over the past 20 years) (112–114), the use of prescription opioids is growing, with 1.3 opioid-related deaths per 100,000 inhabitants in the EU in 2017 (112). Although BZDs are not indicated for pain control and are an ineffective pain medication, they are frequently taken by patients for pain, and taken concomitantly with opioids (115). Efforts to control the growing opioid crisis should include focusing on the use of BZDs as a risk factor.
Use of BZDs is known to increase the risk of misuse of prescribed opioids and the likelihood of future chronic use of opioids (113, 116–118). Some people may use BZDs alongside opioid-based drugs to potentiate or extend their effects, and this may serve as a predictor for more severe polysubstance use problems (119), as concomitant use of BZDs and opioids may result in sedation, respiratory depression, coma, or fatal intoxication (113, 116–118, 120, 121). An Italian study identified that over 20% of individuals who were high-dose misusers of BZDs were also polydrug (17.2%) or former polydrug users (4.3%) of heroin, cocaine, and alcohol (122).
Individuals who have previously used BZDs have more than double the risk of misusing opioids compared with those who have not used BZDs (116). They also have up to nearly a 15-fold greater risk of drug-related death than individuals not prescribed either drug (113). Having a history of BZD use is a risk factor for both “opioid shopping” behavior (where patients obtain overlapping opioid prescriptions from different prescribers that are then filled in multiple pharmacies) and opioid abuse (123). Studies using population health survey findings crosslinked to the Norwegian prescription database show that a history of BZD use raises the chance of being prescribed opioids up to 20 years later in life among those who also used alcohol. Follow-up analyzes also demonstrate that use of BZDs predicts repeated use of opioids 4–7 years later, and that the use of BZDs is a strong predictor of later opioid use (124, 125).
Other European data show that despite warnings in the BZD product labels against using these agents together, concomitant use of BZDs with opioids does occur. In Spain, a study of real-world patterns of opioid use in the Valencia region (~5 million inhabitants) found that almost 25% of people initiating treatment with opioids between 2012 and 2018 had overlapping use of BZDs (126). Similarly, a population-based registry study of BZD use in the Castile and León region (~2.4 million inhabitants) in 2016 reported that almost 25% of individuals using a BZD daily also used opioids (127). Misuse of BZDs and illicit opioids has also been shown to be a problem for hospitals across Europe. In Italy, a top cause of access to emergency medical care was misuse of BZDs in individuals addicted to heroin (128). Italian data analyzing hospital admissions to the addiction unit from 2003 to 2010 also highlighted that 32% of admissions were for BZD abuse, with 25.2% of this patient subgroup showing addiction to BZDs and illicit drugs, including opioids (129). Previous BZD use can also increase the likelihood of chronic opioid use after surgery, with one Finnish study reporting that prior BZD use doubled the probability of chronic opioid use at 12 months after elective orthopedic surgery (130, 131).
5. Conclusion
Insomnia is associated with numerous negative health effects () and chronic insomnia remains a major burden for individuals and healthcare systems globally (111). The lack of training and availability of clinical staff limit the use of CBTi (). BZDs and ZDs have a place in the treatment pathway for chronic insomnia, however, there is also an unmet need as these and other current pharmacological treatments are not licensed for use beyond 4 weeks and so are not aligned with the chronicity of the disease (i.e., symptoms lasting >3 months). The lack of wider CBTi availability and licensed alternative pharmacotherapy options (especially for chronic insomnia) appears to contribute to both undertreatment of chronic insomnia () and widespread use of BZDs and ZDs beyond their recommended duration of treatment.
In patients who have been using BZDs for longer than recommended, stopping or reducing the use of BZDs may be difficult due to the withdrawal symptoms. However, long-term use of high doses of BZDs (e.g., in individuals where the dosage was increased over time due to tolerance developing) induces a severe disruption of sleep microstructure (102), so any initial efficacy in improving symptoms diminishes over time. Patients with symptoms of BZD dependence and addictions are not coming forward to HCPs and clinics, so it is challenging for doctors to recognize these patients. To date, there is little research on characterization of high-dose BZD users in chronic insomnia, so the next step is to ensure that clinicians can identify patients with risk factors for escalation of BZD use.
Guidance is available for deprescribing and withdrawing of BZDs (132, 133), however not all HCPs may be familiar with or use this. Evidence has shown that in both short- and long-term scenarios, deprescribing BZDs by gradual tapering in combination with non-pharmacological support is more likely to succeed than gradual tapering alone (134). A multicenter, randomized interventional study in Belgium recently looked at strategies to support BZD discontinuation in primary care (135). This study found that the use of blended care, which combines the use of an interactive educational e-tool with face-to-face clinical consultations with the care provider, provides a complementary tool that enables the BZD discontinuation process to be tailored to the personal style of the GP and the needs of the patient.
In conclusion, there is a need to break the vicious cycle of chronic insomnia: chronic insomnia is a disorder that has substance use and dependence as major comorbidities (), and yet it is treated with drugs such as BZDs and ZDs that carry a risk of tolerance, dependence, and misuse (for longer than recommended, at escalated doses over time, and/or in patients who are at risk of side effects). For patients with chronic insomnia, BZDs are likely to remain an appropriate option for short-term use; however, greater awareness of their limitations and risks when used for longer than recommended should encourage HCPs to stringently adhere to the treatment duration recommendations in clinical guidelines. Ultimately, treatment options suitable for long-term use in chronic insomnia are needed (136).
Funding
This study received funding from Idorsia Pharmaceuticals Ltd. The funder had the following involvement with the study: design and commissioning of the market research studies conducted by Ipsos and IQVIA as described within this manuscript; funding of medical writing support provided by Patrick Foley and Olivia Taylor (NexGen Healthcare Communications, London, United Kingdom).
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1212028/full#supplementary-material
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
MS, IW, CL, FL, and GH: conceptualization. MS, IW, BC, CL, FL, and GH: methodology, investigation, data curation, writing–original outline and draft preparation, and writing–review and editing. All authors contributed to the article and approved the submitted version.
Conflict of interest
BC and CL are employees of Idorsia Pharmaceuticals Ltd. IW was an employee of Idorsia Pharmaceuticals Ltd. at the time of preparation of the manuscript. FL has received payment for consultations, presentations, speaker bureaus, and educational events from Molteni Farmaceutici. GH has received payment for honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Bristol-Meyers Squibb, FEO, Gedeon Richter, Georg Thieme, Heel, Hexal, Hikma, Idorsia, Janssen-Cilag, Jazz, Lundbeck, Medfora, Medice, Medical Tribune, MedScape, MedTrix, Neuraxpharm, Pfizer, Prosomno, Recordati, Repha, Rovi, Sanofi-Aventis, and Schwabe. MS has received consultancy fees from Camurus.
The reviewer TW declared a shared affiliation with the author GH to the handling editor at the time of review.
References
1.
CarleyDWFarabiSS. Physiology of sleep. Diabetes Spectr. (2016) 29:5–9. doi: 10.2337/diaspect.29.1.5
2.
XieLKangHXuQChenMJLiaoYThiyagarajanMet al. Sleep drives metabolite clearance from the adult brain. Science (1979). (2013) 342:373–7. doi: 10.1126/science.1241224
3.
ZielinskiMMcKennaJMcCarleyR. Functions and mechanisms of sleep. AIMS Neurosci. (2016) 3:67–104. doi: 10.3934/Neuroscience.2016.1.67
4.
Lloyd-JonesDMAllenNBAndersonCAMBlackTBrewerLCForakerREet al. Life’s essential 8: updating and enhancing the american heart association’s construct of cardiovascular health: a presidential advisory from the american heart association. Circulation. (2022) 146:E18–43. doi: 10.1161/CIR.0000000000001078
5.
KohyamaJ. Which Is More Important for Health: Sleep Quantity or Sleep Quality?Children. (2021) 8:542. doi: 10.3390/children8070542
6.
ChattuVManzarMKumarySBurmanDSpenceDPandi-PerumalS. The global problem of insufficient sleep and its serious public health implications. Healthcare. (2018) 7:1. doi: 10.3390/healthcare7010001
7.
MorinCMJarrinDC. Epidemiology of Insomnia: Prevalence, Course, Risk Factors, and Public Health Burden. Sleep Med Clin. (2022) 17:173–91. doi: 10.1016/j.jsmc.2022.03.003
8.
AlRasheedMMFekih-RomdhaneFJahramiHPiresGNSaifZAleneziAFet al. The prevalence and severity of insomnia symptoms during COVID-19: A global systematic review and individual participant data meta-analysis. Sleep Med. (2022) 100:7–23. doi: 10.1016/j.sleep.2022.06.020
9.
MaireMLinderSDvořákCMerloCEssigSTalKet al. Prevalence and management of chronic insomnia in Swiss primary care: Cross-sectional data from the “Sentinella” practice-based research network. J Sleep Res. (2020) 29:13121. doi: 10.1111/jsr.13121
10.
Hajak G, SINE Study Group. Study of Insomnia in Europe. Epidemiology of severe insomnia and its consequences in Germany. Eur Arch Psychiatry Clin Neurosci. (2001) 251:49–56. doi: 10.1007/s004060170052
11.
BeckFRichardJBLégerD. Prévalence et facteurs sociodémographiques associés à l’insomnie et au temps de sommeil en France (15-85 ans). Rev Neurol (Paris). (2013) 169:956–64. doi: 10.1016/j.neurol.2013.02.011
12.
MorphyHDunnKMLewisMBoardmanHFCroftPR. Epidemiology of insomnia: A longitudinal study in a UK population. Sleep. (2007) 30:274–80. doi: 10.1093/sleep/30.3.274 PMID:
13.
PalaginiLManniRAgugliaEAmoreMBrugnoliRGirardiPet al. Expert opinions and consensus recommendations for the evaluation and management of insomnia in clinical practice: Joint statements of five Italian scientific societies. Front. Psychiatry. (2020) 11:558. doi: 10.3389/fpsyt.2020.00558
14.
MatosJEChaletFXVaillantCRobertsG. Unmet needs for insomnia patients - Humanistic burden in Europe. Value Health. (2021) 25:S217. doi: 10.1016/j.jval.2021.11.1060
15.
LegerDPoursainB. An international survey of insomnia: Under-recognition and under-treatment of a polysymptomatic condition. Curr Med Res Opin. (2005) 21:1785–92. doi: 10.1185/030079905X65637
16.
RothT. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. (2007) 3:S7–S10. doi: 10.5664/jcsm.26929 PMID:
17.
KhurshidKA. Comorbid Insomnia and Psychiatric Disorders: An Update. Innov Clin Neurosci. (2018) 15:28–32. PMID:
18.
FordDE. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?JAMA. (1989) 262:1479–84. doi: 10.1001/jama.1989.03430110069030
19.
McCallWV. A psychiatric perspective on insomnia. J Clin Psychiatry. (2001) 62:27–32. PMID:
20.
Ancoli-IsraelS. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care. (2006) 12:S221–9. PMID:
21.
BencaRM. Consequences of insomnia and its therapies. J Clin Psychiatry. (2001) 62:33–8. PMID:
22.
OhayonMM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. (2002) 6:97–111. doi: 10.1053/smrv.2002.0186
23.
DaleyMMorinCMLeBlancMGrégoireJ-PSavardJ. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. (2009) 32:55–64. doi: 10.5665/sleep/32.1.55 PMID:
24.
American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine (2014). 383 p.
25.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association (2013).
26.
QaseemAKansagaraDForcieaMACookeMDenbergTDBarryMJet al. Management of chronic insomnia disorder in adults: A clinical practice guideline from the American college of physicians. Ann Intern Med. (2016) 165:125–33. doi: 10.7326/M15-2175
27.
RiemannDBaglioniCBassettiCBjorvatnBDolenc GroseljLEllisJGet al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. (2017) 26:675–700. doi: 10.1111/jsr.12594
28.
MüllerM. Schlafstörungen aus psychiatrischer Sicht. Pychopraxis Neuropraxis. (2022) 25:16–25. doi: 10.1007/s00739-021-00767-4
29.
WilsonSAndersonKBaldwinDDijkD-JEspieAEspieCet al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol. (2019) 33:923–47. doi: 10.1177/0269881119855343
30.
BaglioniCAltenaEBjorvatnBBlomKBotheliusKDevotoAet al. The European academy for cognitive behavioural therapy for insomnia: An initiative of the European Insomnia Network to promote implementation and dissemination of treatment. J Sleep Res. (2020) 29:e12967. doi: 10.1111/jsr.12967
31.
Ministry of Health and Social Policy. Clinical practice guidelines for the management of patients with insomnia in primary care. Madrid (2009). Available at: https://www.martanietopsicologa.com/guias-practicas-trastornos-del-sueno/Guia-practica-clinica-para-el-manejo-de-pacientes-con-insomnio-en-atencio-primaria.pdf (Accessed June 8, 2023).
32.
IstvanMCailletPRousseletMGuerlaisMLaforgueE-JGérardinMet al. Change in the regulatory framework for zolpidem: What is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study. Br J Clin Pharmacol. (2021) 87:3310–9. doi: 10.1111/bcp.14753
33.
De CrescenzoFD’AlòGLOstinelliEGCiabattiniMDi FrancoVWatanabeNet al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. (2022) 400:170–84. doi: 10.1016/S0140-6736(22)00878-9
34.
EPHMRA. EPHMRA Code of Conduct 2022. (2022). Available at: https://www.ephmra.org/sites/default/files/2022-08/EPHMRA%202022%20Code%20of%20Conduct.pdf (Accessed June 8, 2023).
35.
EPHMRA. EPHMRA Anatomical Classification Guidelines V2022. (2022). Available at: https://www.ephmra.org/sites/default/files/2022-01/2022%20ATC%20Guidelines.pdf (Accessed June 8, 2023).
36.
AlthubaitiA. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. (2016) 9:211–7. doi: 10.2147/JMDH.S104807
37.
Teva UK Limited. Melatonin Teva XL 2mg PR Tablets Summary of Product Characteristics. (2023). Available at: https://www.medicines.org.uk/emc/product/13101/smpc/print (Accessed June 6, 2023).
38.
BjorvatnBJernelövSPallesenS. Insomnia–a heterogenic disorder often comorbid with psychological and somatic disorders and diseases: a narrative review with focus on diagnostic and treatment challenges. Front Psychol. (2021) 12:639198. doi: 10.3389/fpsyg.2021.639198
39.
EllisJGPerlisMLEspieCAGrandnerMABastienCHBarclayNLet al. The natural history of insomnia: predisposing, precipitating, coping, and perpetuating factors over the early developmental course of insomnia. Sleep. (2021) 44:zsab095. doi: 10.1093/sleep/zsab095
40.
WrightCDTianiAGBillingsleyALSteinmanSALarkinKTMcNeilDW. A framework for understanding the role of psychological processes in disease development, maintenance, and treatment: the 3P-disease model. Front Psychol. (2019) 10:2498. doi: 10.3389/fpsyg.2019.02498
41.
AuthierNBalayssacDSautereauMZangarelliACourtyPSomogyiAAet al. Benzodiazepine dependence: Focus on withdrawal syndrome. Ann Pharm Fr. (2009) 67:408–13. doi: 10.1016/j.pharma.2009.07.001
42.
LaderM. Benzodiazepines revisited-will we ever learn?Addiction. (2011) 106:2086–109. doi: 10.1111/j.1360-0443.2011.03563.x
43.
RösnerSEnglbrechtCWehrleRHajakGSoykaM. Eszopiclone for insomnia. Cochrane Database Syst Rev. (2018) 10:CD010703. doi: 10.1002/14651858.CD010703.pub2
44.
MaT-TWangZQinXJuCLauWCYManKKCet al. Global trends in the consumption of benzodiazepines and Z-drugs in 67 countries and regions from 2008 to 2018: a sales data analysis. Sleep. (2023) 2023:zsad124. doi: 10.1093/sleep/zsad124
45.
LugoboniFQuaglioG. Exploring the dark side of the moon: The treatment of benzodiazepine tolerance. Br J Clin Pharmacol. (2014) 77:239–41. doi: 10.1111/bcp.12148
46.
FangSYChenCYChangISWuECHChangCMLinKM. Predictors of the incidence and discontinuation of long-term use of benzodiazepines: A population-based study. Drug Alcohol Depend. (2009) 104:140–6. doi: 10.1016/j.drugalcdep.2009.04.017
47.
GentileGLapeyre-MestreMMicallefJ. Combatting the misuse of benzodiazepines and related Z drugs in French general practice: A clinical review. BJGP Open. (2020) 4:101014. doi: 10.3399/bjgpopen20X101014
48.
MattioliIBettiolACrescioliGBonaiutiRPriscoDMannaioniGet al. Hospitalisations related to benzodiazepine, Z-drug, and opioid treatment in Italy: a claim on the risks associated with inappropriate use. Eur J Clin Pharmacol. (2022) 78:1511–9. doi: 10.1007/s00228-022-03354-7
49.
López-PelayoHComaAGualAZaraCLligoñaA. Call for action: Benzodiazepine prescription prevalence analysis shows off-label prescription in one in eleven citizens. Eur Addict Res. (2019) 25:320–9. doi: 10.1159/000502518
50.
ButhSHolzbachRMartensMSNeumann-RundeEMeinersOVertheinU. Problematische medikation von benzodiazepinen, z-substanzen und opioid-analgetika. Dtsch Arztebl Int. (2019) 116:607–14. doi: 10.3238/arztebl.2019.0607
51.
DaviesJRaeTCMontaguL. Long-term benzodiazepine and Z-drugs use in England: a survey of general practice. Br J Gen Pract. (2017) 67:e609–13. doi: 10.3399/bjgp17X691865
52.
AiragnesGLemogneCRenuyAGoldbergMHoertelNRoquelaureYet al. Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: Findings from the CONSTANCES cohort. BMC Public Health. (2019) 19:566. doi: 10.1186/s12889-019-6933-8
53.
UrruSAMPasinaLMinghettiPGiuaC. Role of community pharmacists in the detection of potentially inappropriate benzodiazepines prescriptions for insomnia. Int J Clin Pharm. (2015) 37:1004–8. doi: 10.1007/s11096-015-0166-4
54.
LindenMBärTHelmchenH. Prevalence and appropriateness of psychotropic drug use in old age: results from the Berlin Aging Study (BASE). Int Psychogeriatr. (2004) 16:461–80. doi: 10.1017/S1041610204000420
55.
JanhsenKRoserPHoffmannK. The problems of long-term treatment with benzodiazepines and related substances. Dtsch Ärztebl Int. (2015) 112:1–7. doi: 10.3238/arztebl.2015.0001
56.
EPI-PHARE. Covid-19: Usage des médicaments de ville en France. (2021). Available at: https://www.epi-phare.fr/rapports-detudes-et-publications/covid-19-usage-des-medicaments-rapport-6/ (Accessed June 6, 2023).
57.
BraquehaisMDLusillaPBelMJNavarroMCNasilloVDíazAet al. Dual diagnosis among physicians: a clinical perspective. J Dual Diagn. (2014) 10:148–55. doi: 10.1080/15504263.2014.929331
58.
MorbioliLLugoboniF. High-dose benzodiazepine dependence among health-care professionals: A neglected phenomenon. Med Sci Law. (2021) 61:42–5. doi: 10.1177/0025802420928650
59.
LiebrenzMGehringM-TBuadzeACaflischC. High-dose benzodiazepine dependence: a qualitative study of patients’ perception on cessation and withdrawal. BMC Psychiatry. (2015) 15:116. doi: 10.1186/s12888-015-0493-y
60.
OhayonMMLaderMH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry. (2002) 63:817–25. doi: 10.4088/JCP.v63n0912
61.
AshtonH. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. (2005) 18:249–55. doi: 10.1097/01.yco.0000165594.60434.84
62.
GérardinMVictorri-VigneauCGuerlaisMGuillou-LandreatMGrall-BronnecMJollietP. Benzodiazepines consumption: Does dependence vary with age?Subst Use Misuse. (2014) 49:1417–25. doi: 10.3109/10826084.2014.912226
63.
JohnsonBStreltzerJ. Risks associated with long-term benzodiazepine use. Am Fam Physician. (2013) 88:224–6. PMID:
64.
SoykaM. Treatment of benzodiazepine dependence. New Engl J Med. (2017) 376:1147–57. doi: 10.1056/NEJMra1611832
65.
FacciniMLeoneROpriSCasariRResenteraCMorbioliLet al. Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases. J Psychopharmacol. (2016) 30:1047–53. doi: 10.1177/0269881116647505
66.
AgravatA. ‘Z’-hypnotics versus benzodiazepines for the treatment of insomnia. Prog Neurol Psychiatry. (2018) 22:26–9. doi: 10.1002/pnp.502
67.
MillerPSAricescuAR. Crystal structure of a human GABAA receptor. Nature. (2014) 512:270–5. doi: 10.1038/nature13293
68.
SchelpSABrodnikZDRakowskiDRPultorakKJSambellsATEspañaRAet al. Diazepam concurrently increases the frequency and decreases the amplitude of transient dopamine release events in the nucleus accumbens. J Pharmacol Exp Ther. (2018) 364:145–55. doi: 10.1124/jpet.117.241802
69.
SoykaM. Sedatives and hypnotics abuse. Compr Pharmacol. (2022) 2022:494–509. doi: 10.1016/B978-0-12-820472-6.00033-5
70.
EnginE. GABAA receptor subtypes and benzodiazepine use, misuse, and abuse. Front Psych. (2022) 13:1060949. doi: 10.3389/fpsyt.2022.1060949
71.
GuinaJMerrillB. Benzodiazepines I: Upping the care on downers: The evidence of risks, benefits and alternatives. J Clin Med. (2018) 7:17. doi: 10.3390/jcm7020017
72.
LandoltSRosemannTBlozikEBrünggerBHuberCA. Benzodiazepine and z-drug use in Switzerland: Prevalence, prescription patterns and association with adverse healthcare outcomes. Neuropsychiatr Dis Treat. (2021) 17:1021–34. doi: 10.2147/NDT.S290104
73.
Pfizer. HALCION (triazolam tablets) Prescribing information. (2014) Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017892s047lbl.pdf (Accessed June 8, 2023).
74.
AccordUK. Temazepam Tablets 10mg Summary of Product Characteristics. (2020). Available at: https://www.medicines.org.uk/emc/product/3280/smpc/print (Accessed June 8, 2023).
75.
Genus Pharmaceuticals. Dormagen (lormetazepam) 0.5mg Tablets Summary of Product Characteristics. (2021). AVailable at: https://www.medicines.org.uk/emc/product/5269/smpc/print (Accessed June 8, 2023).
76.
Zentiva. Loprazolam 1mg Tablets Summary of Product Characteristics. (2022). Available at: https://www.medicines.org.uk/emc/product/4192/smpc/print (Accessed June 8, 2023).
77.
Accord UK. Nitrazepam 5 mg Tablets Summary of Product Characteristics. (2020). Available at: https://www.medicines.org.uk/emc/product/5893/smpc (Accessed June 8, 2023).
78.
DrugBank online. Flunitrazepam: DrugBank summary. Available at: https://go.drugbank.com/drugs/DB01544 (Accessed June 8, 2023).
79.
Mylan. Dalmane (flurazepam) 30 mg Capsules Summary of Product Characteristics. (2020). Available at: https://www.medicines.org.uk/emc/product/1726/smpc/print (Accessed June 8, 2023).
80.
Neuroaxpharm UK Ltd. Clonazepam 1 mg Tablets Summary of Product Characteristics. (2023). Available at: https://www.medicines.org.uk/emc/product/13634/smpc (Accessed June 8, 2023).
81.
US Department of Health and Human Services. Nordazepam: Summary. (2023). Available at: https://drugs.ncats.io/drug/67220MCM01 (Accessed June 6, 2023).
82.
GunjaN. The Clinical and Forensic Toxicology of Z-drugs. J Med Toxicol. (2013) 9:155–62. doi: 10.1007/s13181-013-0292-0
83.
National Institute for Health and Care Excellence. Hypnotics and anxiolytics. (2013). Available at: https://bnf.nice.org.uk/treatment-summaries/hypnotics-and-anxiolytics/#overview (Accessed June 6, 2023).
84.
CosciFChouinardG. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. (2020) 89:283–306. doi: 10.1159/000506868
85.
TsengL-YHuangS-TPengL-NChenL-KHsiaoF-Y. Benzodiazepines, z-Hypnotics, and Risk of Dementia: Special Considerations of Half-Lives and Concomitant Use. Neurotherapeutics. (2020) 17:156–64. doi: 10.1007/s13311-019-00801-9
86.
PolyTNIslamMMYangH-CJack LiY-C. Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies. Joint Bone Spine. (2020) 87:241–9. doi: 10.1016/j.jbspin.2019.11.003
87.
ChenLBellJSVisvanathanRHilmerSNEmeryTRobsonLet al. The association between benzodiazepine use and sleep quality in residential aged care facilities: a cross-sectional study. BMC Geriatr. (2016) 16:196. doi: 10.1186/s12877-016-0363-6
88.
GunjaN. In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving. J Med Toxicol. (2013) 9:163–71. doi: 10.1007/s13181-013-0294-y
89.
RichardsonKLokeYKFoxCMaidmentIHowardRSteelNet al. Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. BMC Med. (2020) 18:351. doi: 10.1186/s12916-020-01821-5
90.
HarbourtKNevoONZhangRChanVCroteauD. Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death. Pharmacoepidemiol Drug Saf. (2020) 29:684–91. doi: 10.1002/pds.5004
91.
BarkerMJGreenwoodKMJacksonMCroweSF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. (2004) 18:37–48. doi: 10.2165/00023210-200418010-00004
92.
MovigKLLMathijssenMPMNagelPHAvan EgmondTde GierJJLeufkensHGMet al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev. (2004) 36:631–6. doi: 10.1016/S0001-4575(03)00084-8
93.
PenninkilampiREslickGD. A systematic review and meta-analysis of the risk of dementia associated with benzodiazepine use, after controlling for protopathic bias. CNS Drugs. (2018) 32:485–97. doi: 10.1007/s40263-018-0535-3
94.
LucchettaRCda MataBPMde MastroianniPC. Association between development of dementia and use of benzodiazepines: a systematic review and meta-analysis. Pharmacotherapy. (2018) 38:1010–20. doi: 10.1002/phar.2170
95.
JungMEMetzgerDBHallJ. The long-term but not short-term use of benzodiazepine impairs motoric function and upregulates amyloid β in part through the suppression of translocator protein. Pharmacol Biochem Behav. (2020) 191:172873. doi: 10.1016/j.pbb.2020.172873
96.
CoteurKHenrardGSchoenmakersBLaenenAvan den BroeckKde SutterAet al. Blended care to discontinue BZRA use in patients with chronic insomnia disorder: a pragmatic cluster randomized controlled trial in primary care. Sleep. (2022) 46:zsac278. doi: 10.1093/sleep/zsac278
97.
ChellappaSLAeschbachD. Sleep and anxiety: From mechanisms to interventions. Sleep Med Rev. (2022) 61:101583. doi: 10.1016/j.smrv.2021.101583
98.
MelaragnoAJ. Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance. Focus (Am Psychiatr Publ). (2021) 19:145–60. doi: 10.1176/appi.focus.20200048
99.
TamburinSFedericoAFacciniMCasariRMorbioliLSartoreVet al. Determinants of quality of life in high-dose benzodiazepine misusers. Int J Environ Res Public Health. (2017) 14:38. doi: 10.3390/ijerph14010038
100.
LugoboniFMirijelloAFacciniMCasariRCossariAMusiGet al. Quality of life in a cohort of high-dose benzodiazepine dependent patients. Drug Alcohol Depend. (2014) 142:105–9. doi: 10.1016/j.drugalcdep.2014.06.020
101.
European Monitoring Centre for Drugs and Drug Addiction. The misuse of benzodiazepines among high-risk opioid users in Europe. (2018). Available at: https://www.emcdda.europa.eu/publications/pods/benzodiazepines_en (Accessed June 6, 2023).
102.
ManconiMFerriRMianoSMaestriMBottasiniVZucconiMet al. Sleep architecture in insomniacs with severe benzodiazepine abuse. Clin Neurophysiol. (2017) 128:875–81. doi: 10.1016/j.clinph.2017.03.009
103.
LugoboniFBertoldiACasariRMantovaniEMorbioliLTamburinS. Adult attention-deficit/hyperactivity disorder and quality of life in high-dose benzodiazepine and related Z-drug users. Eur Addict Res. (2020) 26:274–82. doi: 10.1159/000507852
104.
YuN-WChenP-JTsaiH-JHuangC-WChiuY-WTsayW-Iet al. Association of benzodiazepine and Z-drug use with the risk of hospitalisation for fall-related injuries among older people: a nationwide nested case–control study in Taiwan. BMC Geriatr. (2017) 17:140. doi: 10.1186/s12877-017-0530-4
105.
FedericoAMantovaniECasariRBertoldiALugoboniFTamburinS. Adult attention-deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug. J Neural Transm (Vienna). (2021) 128:1109–19. doi: 10.1007/s00702-020-02285-w
106.
WebsterLRKaranS. The Physiology and Maintenance of Respiration: A Narrative Review. Pain Ther. (2020) 9:467–86. doi: 10.1007/s40122-020-00203-2
107.
GuilleminaultC. Benzodiazepines, breathing, and sleep. Am J Med. (1990) 88:S25–8. doi: 10.1016/0002-9343(90)90282-I
108.
VozorisNTFischerHDWangXStephensonALGershonASGruneirAet al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. (2014) 44:332–40. doi: 10.1183/09031936.00008014
109.
MokharAKuhnSToppJDirmaierJHärterMVertheinU. Long-term use of benzodiazepines and Z drugs: A qualitative study of patients’ and healthcare professionals’ perceptions and possible levers for change. BJGP Open. (2019) 3:101626. doi: 10.3399/bjgpopen18X101626
110.
PohontschNJHeserKLöfflerAHaenischBParkerDLuckTet al. General practitioners’ views on (long-term) prescription and use of problematic and potentially inappropriate medication for oldest-old patients–a qualitative interview study with GPs (CIM-TRIAD study). BMC Fam Pract. (2017) 18:22. doi: 10.1186/s12875-017-0595-3
111.
RiemannDSpiegelhalderKEspieCPollmächerTLégerDBassettiCet al. Chronic insomnia: Clinical and research challenges - An agenda. Pharmacopsychiatry. (2011) 44:1–14. doi: 10.1055/s-0030-1267978
112.
KalkmanGAVan Den BrinkWPierceMAtsmaFVissersKCPSchersHJet al. Monitoring opioids in Europe: The need for shared definitions and measuring drivers of opioid use and related harms. Eur Addict Res. (2022) 28:231–40. doi: 10.1159/000521996
113.
PierceMvan AmsterdamJKalkmanGASchellekensAvan den BrinkW. Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018. Eur Psychiatry. (2021) 64:e47. doi: 10.1192/j.eurpsy.2021.2219
114.
BosettiCSantucciCRadrezzaSErthalJBerterameSCorliO. Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990–2016. Eur J Pain. (2019) 23:697–707. doi: 10.1002/ejp.1337
115.
PergolizziJLeQuangJ. Reappraising the use of benzodiazepines in chronic pain patients. Postgrad Med. (2020) 132:10–2. doi: 10.1080/00325481.2020.1725352
116.
CraggAHauJPWooSAKitchenSALiuCDoyle-WatersMMet al. Risk factors for misuse of prescribed opioids: A systematic review and meta-analysis. Ann Emerg Med. (2019) 74:634–46. doi: 10.1016/j.annemergmed.2019.04.019
117.
ThorntonJDDwibediNScottVPonteCDZiedonisDSambamoorthiNet al. Predictors of transitioning to incident chronic opioid therapy among working-age adults in the United States. Am Health Drug Benefits. (2018) 11:12–21. PMID:
118.
ToriMELarochelleMRNaimiTS. Alcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States, 1999-2017. JAMA Netw Open. (2020) 3:e202361. doi: 10.1001/jamanetworkopen.2020.2361
119.
Advisory Council on the Misuse of Drugs. A review of the evidence of use and harms of novel benzodiazepines. (2020). Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/881969/ACMD_report_-_a_review_of_the_evidence_of_use_and_harms_of_novel_benzodiazepines.pdf (Accessed June 8, 2023).
120.
JonesCMMcAninchJK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. (2015) 49:493–501. doi: 10.1016/j.amepre.2015.03.040
121.
TanakaE. Toxicological Interactions Between Alcohol and Benzodiazepines. J Toxicol Clin Toxicol. (2002) 40:69–75. doi: 10.1081/CLT-120002887
122.
ZamboniLPortogheseICongiuAZandonaiTCasariRFusinaFet al. Polysubstance use patterns among high dose benzodiazepine users: A latent class analysis and differences between male and female use. Front Psych. (2022) 13:811130. doi: 10.3389/fpsyt.2022.811130
123.
CepedaMSFifeDKihmMAMastrogiovanniGYuanY. Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse. Clin J Pain. (2014) 30:1051–6. doi: 10.1097/AJP.0000000000000067
124.
SkurtveitSFuruKBramnessJGTverdalA. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later - A follow-up study of 13 390 men and women aged 40-42 years. Pharmacoepidemiol Drug Saf. (2008) 17:626–933. doi: 10.1002/pds.1616
125.
SkurtveitSFuruKBramnessJSelmerRTverdalA. Benzodiazepines predict use of opioids - A follow-up study of 17,074 men and women. Pain Med. (2010) 11:805–14. doi: 10.1111/j.1526-4637.2010.00870.x
126.
HurtadoIRoblesCPeiróSGarcía-SempereALlopis-CardonaFSánchez-SáezFet al. Real-world patterns of opioid therapy initiation in Spain, 2012–2018: A population-based, retrospective cohort study with 957,080 patients and 1,509,488 initiations. Front Pharmacol. (2022) 13:1025340. doi: 10.3389/fphar.2022.1025340
127.
Herrera-GómezFGutierrez-AbejónECriado-EspegelPÁlvarezFJ. The problem of benzodiazepine use and its extent in the driver population: A population-based registry study. Front Pharmacol. (2018) 9:408. doi: 10.3389/fphar.2018.00408
128.
LugoboniFZamboniLCibinMTamburinS. Gruppo InterSERT di Collaborazione Scientifica (GICS). Intravenous misuse of methadone, buprenorphine and buprenorphine-naloxone in patients under opioid maintenance treatment: A cross-sectional multicentre study. Eur Addict Res. (2019) 25:10–9. doi: 10.1159/000496112
129.
FacciniMLeoneRPajuscoBQuaglioGCasariRAlbieroAet al. Lormetazepam addiction: Data analysis from an Italian medical unit for addiction. Risk Manag Healthc Policy. (2012) 5:43–8. doi: 10.2147/RMHP.S31745
130.
OkoliMURondonAJTownsendCBShermanMBIlyasAM. Comprehensive analysis of opioid use after common elective outpatient orthopaedic surgeries. J Am Acad Orthop Surg Glob Res Rev. (2022) 6:226. doi: 10.5435/JAAOSGlobal-D-21-00226
131.
RajamäkiTJMoilanenTPuolakkaPAHietaharjuAJämsenE. Is the preoperative use of antidepressants and benzodiazepines associated with opioid and other analgesic use after hip and knee arthroplasty?Clin Orthop Relat Res. (2021) 479:2268–80. doi: 10.1097/CORR.0000000000001793
132.
LeeJYFarrellBHolbrookAM. Deprescribing benzodiazepine receptor agonists taken for insomnia: a review and key messages from practice guidelines. Pol Arch Intern Med. (2019) 129:43–9. doi: 10.20452/pamw.4391
133.
PottieKThompsonWDaviesSGrenierJSadowskiCAWelchVet al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. (2018) 64:339–51. PMID:
134.
SoniAThiyagarajanAReeveJ. Feasibility and effectiveness of deprescribing benzodiazepines and Z-drugs: systematic review and meta-analysis. Addiction. (2023) 118:7–16. doi: 10.1111/add.15997
135.
CoteurKVan NulandMSchoenmakersBAnthierensSVan den BroeckK. Implementing Blended Care to Discontinue Benzodiazepine Receptor Agonist Use for Insomnia: Process Evaluation of a Pragmatic Cluster Randomized Controlled Trial. JMIR Form Res. (2023) 7:e43738. doi: 10.2196/43738
136.
EllisJFerini-StrambiLGarcía-BorregueroDHeidbrederAO’ReganDParrinoLet al. Chronic Insomnia Disorder across Europe: Expert Opinion on Challenges and Opportunities to Improve Care. Healthcare. (2023) 11:716. doi: 10.3390/healthcare11050716
Summary
Keywords
benzodiazepines, dependence, insomnia, sleep, therapy, opioids
Citation
Soyka M, Wild I, Caulet B, Leontiou C, Lugoboni F and Hajak G (2023) Long-term use of benzodiazepines in chronic insomnia: a European perspective. Front. Psychiatry 14:1212028. doi: 10.3389/fpsyt.2023.1212028
Received
25 April 2023
Accepted
20 July 2023
Published
02 August 2023
Volume
14 - 2023
Edited by
Thomas Pollmächer, Klinikum Ingolstadt, Germany
Reviewed by
Marike Lancel, University of Groningen, Netherlands; Emily E. Hartwell, United States Department of Veterans Affairs, United States; Thomas Christian Wetter, University of Regensburg, Germany
Updates
Copyright
© 2023 Soyka, Wild, Caulet, Leontiou, Lugoboni and Hajak.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michael Soyka, Michael.Soyka@med.uni-muenchen.de
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.